Objective: To assess the PREEMPT protocol modifications that have developed in clinical practice over time.
Background: The United States Food and Drug Administration approved the 155-unit fixed-dose, fixed-site PREEMPT protocol of onabotulinumtoxinA (BoNT-A) injections for migraine prevention 9 years ago.
Methods: This is an anonymous survey with free text response options of Headache Medicine clinicians.
Results: Out of the 878 contacted Headache Medicine clinicians, 182 (20.7%) completed the survey. Of the 182 respondents, 141 (77.5%) reported that they did not always follow the PREEMPT protocol. Of the 182 respondents, 128 (70%) changed the number of injections, 115 (63%) changed the total units of BoNT-A injected, 105 (57.7%) altered the location of injection sites (58%); 101 (55.5%) do not aspirate to ensure the absence of blood return; 22 (12.1%) changed the dilution; and 4 (2.2%) added lidocaine. The main reported reasons for changes in number, dose, and location of injections included adapting to the patients' pain, anatomy, and preferences.
Conclusions: The wide inter- and intra-personal variations in BoNT-A injections for chronic migraine prevention seen in this survey raise concerns about the standardization of the procedure and suggest that an advisory protocol containing more evidence and discussion of the reasoning behind the recommendations might be more helpful than the current prescriptive protocol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/head.13823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cross-Sectional Analyses to Assess the Clinical Safety and Effectiveness of Bisoprolol in Patients With Non-obstructive Coronary Artery Disease Who Underwent Percutaneous Coronary Intervention: A Post-hoc Analysis.
Cureus
December 2024
Medical Strategic Affairs, Torrent Pharmaceuticals Ltd., Ahmedabad, IND.
Introduction: Elevated central aortic pressure, cardiac output and peripheral vascular resistance contribute to high morbidity in relation to end organ dysfunction in obstructive and non-obstructive coronary artery disease (NOCAD) cases despite revascularization. Bisoprolol preempts further progression of left ventricular dysfunction in such cases due to anti-ischemic and anti-hypertensive effects, further extending its evaluation in local Indian settings.
Methods: Post-hoc analyses of NOCAD patients with epicardial stenosis (N=378, 30 to 70% stenosis) from cross-sectional analyses conducted across eighty centers in India.
Predicting dropout and non-response to psychotherapy for personality disorders: A study protocol focusing on therapist, patient, and the therapeutic relationship.
BMC Psychol
November 2024
Department of Psychology, Catholic University of Sacred Heart of Milan, Milan, Italy.
Background: The abandonment of psychotherapeutic treatments is influenced by various factors, including patient characteristics, therapist traits, and the therapeutic relationship. Despite the well-documented importance of these factors, limited empirical research has focused on the role of the therapeutic relationship and the characteristics of therapist-patient dyads in predicting treatment dropout. This study protocol outlines a longitudinal research project aimed at predicting dropout and non-response in psychotherapy for individuals with personality disorders.
View Article and Find Full Text PDFQuality assessment and control of unprocessed anatomical, functional, and diffusion MRI of the human brain using .
bioRxiv
October 2024
Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Quality control of MRI data prior to preprocessing is fundamental, as substandard data are known to increase variability spuriously. Currently, no automated or manual method reliably identifies subpar images, given pre-specified exclusion criteria. In this work, we propose a protocol describing how to carry out the visual assessment of T1-weighted, T2-weighted, functional, and diffusion MRI scans of the human brain with the visual reports generated by .
View Article and Find Full Text PDF"Prompt" for PREEMPT: Dotting the I's and Crossing the T's With Ultrasound.
J Ultrasound Med
October 2024
Department of Physical Medicine and Rehabilitation, Mubarak Alkabeer Hospital, Jabriya, Kuwait.
The management of chronic migraine (CM) underwent a significant shift with the introduction of onabotulinumtoxin A (BoNT-A) injections following the landmark PREEMPT trial in 2010. Despite its efficacy, the existing injection protocol lacks precision, prompting a call for revision in light of modern ultrasound (US)-guided techniques. This article highlights the potential of US-guided injections to enhance accuracy, safety, and efficacy in CM treatment.
View Article and Find Full Text PDFEffectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine.
Toxins (Basel)
May 2024
Headache Clinic, Neurology Department, Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Article Synopsis
- Chronic migraine (CM) significantly impacts adolescents, and a study aimed to evaluate the safety and effectiveness of onabotulinumtoxinA (BTX-A) in treating these cases while reviewing existing pediatric literature.
- The study included 20 patients under 18, revealing that 55% of participants saw a significant reduction in monthly headache days after 6 months, and 57.1% continued to show improvement at the 12-month mark.
- No adverse effects were reported, suggesting that BTX-A is a safe and effective treatment for adolescents with CM who do not respond to traditional oral medications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!